FSCB Activators are a diverse group of chemical compounds that engage with the signaling cascades pivotal for the functionality and activity of FSCB. These activators predominantly exert their effects by modulating the levels of cyclic nucleotides within cells. Elevation of intracellular cAMP is a common pathway through which several of these activators operate, leading to the activation of protein kinase A (PKA). PKA is known to phosphorylate proteins that are crucial for processes such as sperm capacitation, where FSCB plays a role. The increase in cAMP is achieved through different mechanisms, including inhibition of phosphodiesterases that normally degrade cAMP, or through the action of analogs that mimic cAMP itself. This results in the enhancement of PKA activity and subsequent phosphorylation of target proteins that are part of the signaling pathways associated with FSCB.
In addition to cAMP-mediated pathways, some activators focus on increasing intracellular cGMP levels, which in turn activate protein kinase G (PKG). PKG is another kinase that can phosphorylate substrates involved in similar biological processes as PKA. The specific action of these activators is to inhibit enzymes that break down cGMP or to provide analogs that act like cGMP, thus fostering an environment conducive to PKG activation. The outcome of these kinase activities is the potential phosphorylation and activation of proteins within the signal transduction pathways, including FSCB, which is integral to the proper functioning of these biological systems.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Inhibits phosphodiesterases, increasing cAMP which activates PKA; this enhances phosphorylation of proteins in sperm motility pathways where FSCB is a component. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 50 g 100 g 250 g 1 kg 5 kg | $33.00 $67.00 $97.00 $192.00 $775.00 | 13 | |
Non-selective phosphodiesterase inhibitor that increases cAMP levels, potentially enhancing PKA activity and the phosphorylation state of FSCB. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Phosphodiesterase inhibitor that increases cGMP levels, potentially enhancing protein kinase G (PKG) activity which may phosphorylate FSCB. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Selective PDE4 inhibitor that raises cAMP levels, potentially enhancing PKA activity and the phosphorylation of proteins including FSCB. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
cAMP analog that activates PKA, potentially increasing phosphorylation of proteins within pathways where FSCB functions. | ||||||
8-Bromo-cGMP | 51116-01-9 | sc-200316 sc-200316A | 10 mg 50 mg | $104.00 $354.00 | 7 | |
cGMP analog that activates PKG which may lead to the phosphorylation of proteins in pathways involving FSCB. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
PDE3 inhibitor that increases cAMP levels, potentially enhancing PKA activity and subsequent phosphorylation of FSCB. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
PDE3 inhibitor that raises cAMP levels, potentially increasing PKA activity and phosphorylation of proteins in pathways with FSCB. | ||||||
Tadalafil | 171596-29-5 | sc-208412 | 50 mg | $180.00 | 13 | |
PDE5 inhibitor that increases cGMP levels, potentially enhancing PKG activity and phosphorylation of proteins including FSCB. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $526.00 $735.00 $16653.00 | 7 | |
A PDE5 inhibitor that may increase cGMP levels, potentially leading to enhanced PKG activity and phosphorylation of proteins like FSCB. | ||||||